Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
SIMPLE SUMMARY: Stage IV (metastatic) prostate cancer remains an incurable disease despite many treatment advances in recent years. Approximately a quarter of men with advanced prostate cancer have alterations in DNA repair pathways, namely, homologous recombination repair (HRR). Poly(ADP-ribose) po...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9736565/ https://www.ncbi.nlm.nih.gov/pubmed/36497408 http://dx.doi.org/10.3390/cancers14235922 |